Enveric Biosciences Further Enhances Intellectual Property Estate with New U.S. Patent Issuance
New patent marks Enveric's 23rd issued U.S. patent for novel neuroplastogen molecules, increasing Enveric's intellectual property footprint and supporting the potential for pipeline expansion CAMBRIDGE, Mass. — Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or
(Financial Post, 2025-10-16T12:35:36Z)